about
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapyIxabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialDifferential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelPotential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsalphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients.Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoPrognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancerTopoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerTP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy.PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary.A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleuraPaclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer.A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.Eccrine syringofibroadenoma treated with carbon dioxide laser.The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts: Report of a Unique Case With Immunohistochemical and Molecular Studies.Detection of Helicobacter pylori in raw bovine milk by fluorescence in situ hybridization (FISH).Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
P50
Q27851526-0B7C9BE9-87CF-46DC-92DB-213262403087Q28534786-A210DD87-3701-4408-87C6-E6C55EDD2CFBQ28728830-4760448E-6880-4BC0-80C8-47987BEA01DCQ33359798-9B305BE8-D345-4BAE-8571-9C376F9D3A88Q33385663-41FC5228-A346-4B71-BC8E-599A21492DA5Q33570512-8538F572-0957-4EF0-9D20-D18ED8662DABQ33812042-61C863AF-43E7-4085-A078-DEFCB71915D4Q33830446-31F71DB0-258E-47B2-828F-CC29DA9AE1DCQ34010867-90040E63-268A-41DB-AA79-91286D371748Q34566972-726AC346-D262-4ED9-A887-4DB9BFFB08F8Q34640536-B4CBCE84-7D18-463C-A6E5-EE567AD0FBD7Q34907190-1D2ECA6A-6347-47EA-BEF6-5ACECB514940Q35663809-64990297-2DD6-49DA-9EA1-EA36BDA09AA6Q35744973-2DC6F54C-BB8D-45EB-9160-DD04B4DF2608Q36383433-EB05D962-F75A-44CE-B6FD-52692A8B958AQ36402262-C71D668E-A6D4-4805-9409-5E0D4E275242Q36907273-79FCD6A0-D514-448B-9E85-7A9A8E5DE379Q37362747-6D09F86E-0D70-4DC2-B550-D708052F3CEEQ37406658-4BEA7C25-3105-43D1-AC6B-B1B2D4159D2FQ37877173-F33263BF-82B0-43E1-BCF0-3012D0AAB157Q38077381-A3B06055-560E-4923-9897-5EB4F1785BDCQ38462629-65E46599-B87B-436F-B80F-DA90DDF08640Q38600659-D15B38DF-58D9-4972-9219-6F7B2DD32945Q39638185-3D6715B6-FA75-4B4C-B778-EC61C7EE7311Q41163863-421486D2-1CED-49B3-A048-CCF34C612AB4Q41487406-9198943E-D574-4479-B35A-D800B33431F8Q42042257-073A0814-90D0-47ED-9612-FD3346986829Q43055437-AE5B7823-3623-4E92-81EB-99D260AEB219Q43174266-3F33C1DE-D1BB-421F-8F19-9D6669253970Q44294451-1DE7B2D5-5DFC-49AC-97A2-A6D16D7D13FBQ44703903-7E8D3E81-42BF-43C3-8DA2-A064555301B7Q45094655-1E474091-9435-4F80-9486-8A65C3BC7711Q45944786-302D637A-E05D-4FB1-95BE-736108692088Q46362755-DA7958E7-E0F4-46AB-88DA-8242F8B12096Q47344144-3E9AFD90-4431-40FC-8C47-B6A3FB56D743Q51096608-12BC11A6-0F9E-4918-8D78-48870C98CB38Q53025401-4BBB8484-5690-4007-824D-AD5E488E9F9AQ53211247-8A3F755C-0276-4896-929A-E808F947E3CFQ53773126-81208B1E-5776-48D5-8DBD-B8E2E0485590Q54286282-E4980A30-55C0-4605-9B8D-5ABD0D1CD491
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mattheos Bobos
@ast
Mattheos Bobos
@en
Mattheos Bobos
@es
Mattheos Bobos
@sl
type
label
Mattheos Bobos
@ast
Mattheos Bobos
@en
Mattheos Bobos
@es
Mattheos Bobos
@sl
prefLabel
Mattheos Bobos
@ast
Mattheos Bobos
@en
Mattheos Bobos
@es
Mattheos Bobos
@sl
P106
P1153
57192404508
6506095616
P21
P31
P496
0000-0001-5662-9201